FDA Clears Second Reykjavik Drug Substance Suite for SIMLANDI, Adding Capacity but Not Removing Single-Site Risk

What happened

On October 5, 2026, the FDA approved the use of Alvotech's second drug substance suite at its Reykjavik facility for production of AVT02, the active ingredient in SIMLANDI, its Humira biosimilar. This approval allows Alvotech to manufacture AVT02 drug substance for the U.S. market in either of its two on-site suites, thereby increasing production flexibility and potential capacity. The decision is a modest positive regulatory signal, suggesting the FDA has accepted the additional suite's compliance for AVT02 specifically. However, the approval does not address the company's broader manufacturing deficiencies that led to the November 2025 complete response letter for AVT05, nor does it mitigate the concentration risk of a single Icelandic facility pledged under $1.1 billion of secured debt. With all late-stage assets still depending on Reykjavik's quality systems, this incremental capacity addition is unlikely to alter the fundamental risk-reward balance.

Implication

The additional capacity could support higher SIMLANDI volumes if demand grows, but Humira biosimilar competition is intense and pricing pressure remains severe. The approval may signal incremental progress on manufacturing quality, yet it is limited to AVT02 and does not indicate that the facility-wide issues behind the AVT05 CRL are resolved. The single-site concentration risk persists, and any future FDA enforcement action could disrupt all products, regardless of the number of suites. Alvotech's leverage and negative equity mean that even modest operational setbacks could have outsized equity impact. Investors should await clear evidence of AVT05 resubmission and positive free cash flow before altering positions, with an attractive entry near $3.75 and a trim above $8.

Thesis delta

The FDA approval of a second AVT02 drug substance suite slightly improves manufacturing flexibility but does not change the central WAIT thesis. The main risks—AVT05 CRL, single-site dependency, high leverage—remain unchanged. Therefore, no material shift in investment stance is warranted.